Phaseline

Targets › COMP

COMP (Cartilage oligomeric matrix protein): drug programs, companies and trials

1 program from 1 company in 4 trials: 2 Phase 3, 2 Phase 2; Neurology; next expected readout Dec 2026.

Plays a role in the structural integrity of cartilage via its interaction with other extracellular matrix proteins such as the collagens and fibronectin. Can mediate the interaction of chondrocytes with the cartilage extracellular matrix through interaction with cell surface integrin receptors. (UniProt, P49747)

Open in Phaseline: the race on COMP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Dianthus TherapeuticsClaseprubart
complement C5 inhibitor
FCER2, COMPPhase 3Myasthenia Gravis, Generalized; Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor NeuropathyDec 2026

Conditions

Myasthenia Gravis, Generalized (2) Chronic Inflammatory Demyelinating Polyneuropathy (1) Multifocal Motor Neuropathy (1)

Modalities

antibody (1)

Companies

Dianthus Therapeutics (1)

Related targets

FCER2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.